Citi raised the firm’s price target on Bristol Myers (BMY) to $64 from $60 and keeps a Neutral rating on the shares. The firm views the company’s Q4 results as strong. It believes pipeline wins are key for share upside going forward.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Reiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target
- Bristol-Myers Squibb Bets On New Growth Engines
- Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target
- Truist incrementally positive on Bristol Myers after Bayer asundexian data
- TrumpRx website using technology from GoodRx, STAT says